Author: Kumari G. Lokugamage; Adam Hage; Craig Schindewolf; Ricardo Rajsbaum; Vineet D. Menachery
Title: SARS-CoV-2 is sensitive to type I interferon pretreatment Document date: 2020_3_9
ID: 2w0zr9c0_43
Snippet: can be determined. In addition, use of type III IFN, which is predicted to have utility in the 250 respiratory tract, could offer another means for effective treatment for SARS-CoV-2. 251 . CC-BY-NC 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi. org/10.1101 org/10. /2020 In addition to treatment, the sensitivity to type I IFN may also.....
Document: can be determined. In addition, use of type III IFN, which is predicted to have utility in the 250 respiratory tract, could offer another means for effective treatment for SARS-CoV-2. 251 . CC-BY-NC 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi. org/10.1101 org/10. /2020 In addition to treatment, the sensitivity to type I IFN may also have implications for 252 animal model development. For SARS-CoV, mouse models that recapitulate human disease 253 were developed through virus passage in immune competent mice (46). Similarly, mouse 254 models for MERS-CoV required adaptation in mice that had genetic modifications of their 255 dipeptidyl-peptidase 4 (DPP4), the receptor for 48) . However, each of these 256 MERS-CoV mouse models still retained full immune capacity. In contrast, SARS-CoV-2 257 sensitivity to type I IFN may signal the need to use an immune deficient model to develop 258 relevant disease. While initial work has suggested incompatibility to SARS-CoV-2 infection in 259 mice based on receptor usage (8), the type I IFN response may be a second major barrier that 260 needs to be overcome. Similar to the emergent Zika virus outbreak, the use of type I IFN 261 receptor knockout mice or type I IFN receptor blocking antibody may be necessary to develop a 262 useful SARS-CoV-2 animal models for therapeutic testing (49). 263
Search related documents:
Co phrase search for related documents- animal model and deficient model: 1, 2, 3, 4, 5
- animal model and dipeptidyl peptidase: 1, 2, 3, 4, 5, 6
- animal model and effective treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- animal model and human disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- animal model and ifn response: 1, 2, 3, 4, 5, 6, 7, 8, 9
- animal model and IFN type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- animal model and IFN type sensitivity: 1, 2
- animal model and immune competent mouse: 1
- animal model and knockout mouse: 1
- animal model and mouse model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- animal model and overcome need: 1, 2, 3
- animal model and receptor usage: 1, 2, 3
- animal model and relevant disease: 1, 2, 3, 4, 5
- animal model and require adaptation: 1, 2
- animal model and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
- animal model and sars animal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- animal model and sars animal model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- animal model and SARS effective treatment: 1, 2, 3, 4
- animal model and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
Co phrase search for related documents, hyperlinks ordered by date